depression from semaglutide Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database GLP-1 diabetes drugs could stop

Insurance coverage or cost Tirzepatide is comparatively new in the market and can sometimes be more expensive or less frequently covered by insurance plans than semaglutide

This necessitates regular monitoring of thyroid function during active weight loss phases to avoid overtreatment, which can cause symptoms of hyperthyroidism including palpitations, anxiety, and bone loss

Administered by intramuscular (I M.) or intravenous (I V.) injection

Key Findings from a Large-Scale Study A large real-world study using the TriNetX Analytics Network (20102022) analyzed outcomes in 5,291 PV patients treated with GLP-1 RAs compared with 79,027 untreated patients